On Wednesday, Allogene Therapeutics Inc (ALLO) stock saw a decline, ending the day at $2.72 which represents a decrease of $-0.12 or -4.23% from the prior close of $2.84. The stock opened at $2.86 and ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given ...

Representatives of the city of Joplin, the school district and the Joplin Area Chamber of Commerce gathered at a ceremony ...

A formal ceremony took place today following the start of construction on Joplin’s new fiber-optic network. A groundbreaking ...

ALLO Fiber has kicked off the return of ALLO for Education, a program where they support local schools throughout their fiberhoods. The program's success in the past has been a benefit to their ...

Allogene Therapeutics Inc (ALLO) reports a strong cash position and promising clinical progress, despite facing competitive ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

A groundbreaking in Joplin celebrates what officials hope will be a step towards a more connected city. City leaders joined ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...